AI assistant
Invivyd, Inc. — Director's Dealing 2021
Aug 6, 2021
33564_dirs_2021-08-05_315f12cb-1f61-45ff-bbe1-79f0e0fa3544.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Adagio Therapeutics, Inc. (ADGI)
CIK: 0001832038
Period of Report: 2021-08-05
Reporting Person: Gerngross Tillman U. (Director, Chief Executive Officer, 10% Owner)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 1985295 | Indirect |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Series A Preferred Stock | $ | Common Stock (25000000) | Indirect | ||
| Series B Preferred Stock | $ | Common Stock (220380) | Indirect | ||
| Series C Preferred Stock | $ | Common Stock (640320) | Indirect | ||
| Stock Option (Right to Buy) | $10.14 | 2031-05-06 | Common Stock (3419345) | Direct | |
| Stock Option (Right to Buy) | $12.80 | 2031-07-03 | Common Stock (962825) | Direct |
Footnotes
F1: These shares are held by Adimab, LLC (the "LLC"). The Reporting Person is an officer and member of the Board of Directors of the LLC and, as such, may be deemed to have shared voting and investment power with respect to the shares held by the LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F2: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock is convertible at any time at the option of the holder, without payment of additional consideration, into 5 shares of Common Stock, has no expiration date and is expected to automatically convert into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock.
F3: One quarter (1/4) of the options shall vest on May 7, 2022, and thereafter, the remainder of the options shall vest in 36 equal monthly installments
on the 7th day of each month, subject to the Reporting Person's continuous service on each vesting date.
F4: One quarter (1/4) of the options shall vest on July 4, 2022, and thereafter, the remainder of the options shall vest in 36 equal monthly installments
on the 4th day of each month, subject to the Reporting Person's continuous service on each vesting date.